Oxycodone decreases anxiety-like behavior in the elevated plus-maze test in male and female rats.
Journal
Behavioural pharmacology
ISSN: 1473-5849
Titre abrégé: Behav Pharmacol
Pays: England
ID NLM: 9013016
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
entrez:
10
8
2022
pubmed:
11
8
2022
medline:
13
8
2022
Statut:
ppublish
Résumé
The prescription opioid oxycodone is widely used for the treatment of pain in humans. Oxycodone misuse is more common among people with an anxiety disorder than those without one. Therefore, oxycodone might be misused for its anxiolytic properties. We investigated if oxycodone affects anxiety-like behavior in adult male and female rats. The rats were treated with oxycodone (0.178, 0.32, 0.56, or 1 mg/kg), and anxiety-like behavior was investigated in the elevated plus-maze test. Immediately after the elevated plus-maze test, a small open field test was conducted to determine the effects of oxycodone on locomotor activity. In the elevated plus-maze test, oxycodone increased the percentage of time spent on the open arms, the percentage of open arm entries, time on the open arms, open arm entries, and the distance traveled. The males treated with vehicle had a lower percentage of open arm entries than the females treated with vehicle, and oxycodone treatment led to a greater increase in the percentage of open arm entries in the males than females. Furthermore, the females spent more time on the open arms, made more open arm entries, spent less time in the closed arms, and traveled a greater distance than the males. In the small open field test, treatment with oxycodone did not affect locomotor activity or rearing. Sex differences were observed; the females traveled a greater distance and displayed more rearing than the males. In conclusion, oxycodone decreases anxiety-like behavior in rats, and oxycodone has a greater anxiolytic-like effect in males than females.
Identifiants
pubmed: 35947068
doi: 10.1097/FBP.0000000000000690
pii: 00008877-202209000-00004
pmc: PMC9373716
mid: NIHMS1824008
doi:
Substances chimiques
Anti-Anxiety Agents
0
Oxycodone
CD35PMG570
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
418-426Subventions
Organisme : NIDA NIH HHS
ID : R01 DA046411
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA049470
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Adamec RE, Sayin U, Brown A (1991). The effects of corticotrophin releasing factor (CRF) and handling stress on behavior in the elevated plus-maze test of anxiety. J Psychopharmacol 5:175–186.
Alexeeva EV, Nazarova GA, Sudakov SK (2012). Effects of peripheral μ, δ, and Κ-opioid receptor agonists on the levels of anxiety and motor activity of rats. Bull Exp Biol Med 153:720–721.
Boyd CJ, McCabe SE, Cranford JA, Young A (2006). Adolescents’ motivations to abuse prescription medications. Pediatrics 118:2472–2480.
Bruijnzeel AW, Lewis B, Bajpai LK, Morey TE, Dennis DM, Gold M (2006). Severe deficit in brain reward function associated with fentanyl withdrawal in rats. Biol Psychiatry 59:477–480.
Bruijnzeel AW, Qi X, Guzhva LV, Wall S, Deng JV, Gold MS, et al. (2016). Behavioral characterization of the effects of cannabis smoke and anandamide in rats. PLoS One 11:e0153327.
Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, Munafò MR (2013). Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 14:365–376.
Centers for Disease Control and Prevention, N.C.f.H.S. (2021). Multiple cause of death 1999-2019. CDC WONDER Online Database, released 12/2020. (10/18/2021).
Chan S, Edwards SR, Wyse BD, Smith MT (2008). Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat. Clin Exp Pharmacol Physiol 35:295–302.
Chellian R, Behnood-Rod A, Wilson R, Febo M, Bruijnzeel AW (2021). Adolescent nicotine treatment causes robust locomotor sensitization during adolescence but impedes the spontaneous acquisition of nicotine intake in adult female Wistar rats. Pharmacol Biochem Behav 207:173224.
Chellian R, Behnood-Rod A, Wilson R, Wilks I, Knight P, Febo M, Bruijnzeel AW (2020). Exposure to smoke from high-but not low-nicotine cigarettes leads to signs of dependence in male rats and potentiates the effects of nicotine in female rats. Pharmacol Biochem Behav 2020;196:172998.
Chen Q, Larochelle MR, Weaver DT, Lietz AP, Mueller PP, Mercaldo S, et al. (2019). Prevention of prescription opioid misuse and projected overdose deaths in the United States. JAMA Netw Open 2:e187621.
Collins D, Reed B, Zhang Y, Kreek MJ (2016). Sex differences in responsiveness to the prescription opioid oxycodone in mice. Pharmacol Biochem Behav 148:99–105.
Craft RM (2008). Sex differences in analgesic, reinforcing, discriminative, and motoric effects of opioids. Exp Clin Psychopharmacol 16:376–385.
Domonkos E, Borbélyová V, Csongová M, Bosý M, Kačmárová M, Ostatníková D, et al. (2017). Sex differences and sex hormones in anxiety-like behavior of aging rats. Horm Behav 93:159–165.
Domonkos E, Hodosy J, Ostatníková D, Celec P (2018). On the role of testosterone in anxiety-like behavior across life in experimental rodents. Front Endocrinol (Lausanne) 9:441.
Febo M, González-Rodríguez LA, Capó-Ramos DE, González-Segarra NY, Segarra AC (2003). Estrogen-dependent alterations in D2/D3-induced G protein activation in cocaine-sensitized female rats. J Neurochem 86:405–412.
Feingold D, Brill S, Goor-Aryeh I, Delayahu Y, Lev-Ran S (2017). Misuse of prescription opioids among chronic pain patients suffering from anxiety: a cross-sectional analysis. Gen Hosp Psychiatry 47:36–42.
File SE (1990). One-trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze. Psychopharmacology (Berl) 100:281–282.
Fujii K, Koshidaka Y, Adachi M, Takao K (2019). Effects of chronic fentanyl administration on behavioral characteristics of mice. Neuropsychopharmacol Rep 39:17–35.
Gros DF, Milanak ME, Brady KT, Back SE (2013). Frequency and severity of comorbid mood and anxiety disorders in prescription opioid dependence. Am J Addict 22:261–265.
Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW (1990). Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 100:558–559.
Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM (2017). Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 national survey on drug use and health. Ann Intern Med 167:293–301.
Hayashi ML, Rao BS, Seo JS, Choi HS, Dolan BM, Choi SY, et al. (2007). Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proc Natl Acad Sci U S A 104:11489–11494.
Hogg S (1996). A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav 54:21–30.
Holtman JR Jr, Wala EP (2006). Characterization of the antinociceptive effect of oxycodone in male and female rats. Pharmacol Biochem Behav 83:100–108.
Huang L, Edwards SR, Smith MT (2005). Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague–Dawley rats: influence of streptozotocin-induced diabetes. Pharm Res 22:1489–1498.
Kane S (2021). Oxycodone, ClinCalc DrugStats Database, Version 2021.10. ClinCalc: https://clincalc.com/DrugStats/Drugs/Oxycodone . Updated September 15, 2021. [Accessed October 25, 2021].
Knight P, Chellian R, Wilson R, Behnood-Rod A, Panunzio S, Bruijnzeel AW (2021). Sex differences in the elevated plus-maze test and large open field test in adult Wistar rats. Pharmacol Biochem Behav 204:173168.
Kõks S, Soosaar A, Võikar V, Bourin M, Vasar E (1999). BOC-CCK-4, CCK(B)receptor agonist, antagonizes anxiolytic-like action of morphine in elevated plus-maze. Neuropeptides 33:63–69.
Korte SM, De Boer SF, Bohus B (1999). Fear-potentiation in the elevated plus-maze test depends on stressor controllability and fear conditioning. Stress 3:27–40.
Kristensen K, Christensen CB, Christrup LL (1994). The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 56:45–50.
Kudryavtseva NN, Gerrits MA, Avgustinovich DF, Tenditnik MV, Van Ree JM (2004). Modulation of anxiety-related behaviors by mu- and kappa-opioid receptor agonists depends on the social status of mice. Peptides 25:1355–1363.
Liu YL, Yan LD, Zhou PL, Wu CF, Gong ZH (2009). Levo-tetrahydropalmatine attenuates oxycodone-induced conditioned place preference in rats. Eur J Pharmacol 602:321–327.
Maguire P, Tsai N, Kamal J, Cometta-Morini C, Upton C, Loew G (1992). Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors. Eur J Pharmacol 213:219–225.
Martins SS, Fenton MC, Keyes KM, Blanco C, Zhu H, Storr CL (2012). Mood and anxiety disorders and their association with non-medical prescription opioid use and prescription opioid-use disorder: longitudinal evidence from the national epidemiologic study on alcohol and related conditions. Psychol Med 42:1261–1272.
Martins SS, Keyes KM, Storr CL, Zhu H, Chilcoat HD (2009a). Pathways between nonmedical opioid use/dependence and psychiatric disorders: results from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend 103:16–24.
Martins SS, Storr CL, Zhu H, Chilcoat HD (2009b). Correlates of extramedical use of OxyContin versus other analgesic opioids among the US general population. Drug Alcohol Depend 99:58–67.
Monory K, Greiner E, Sartania N, Sallai L, Pouille Y, Schmidhammer H, et al. (1999). Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinans. Life Sci 64:2011–2020.
Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT (2007). Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 132:289–300.
Pellow S, File SE (1986). Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav 24:525–529.
Pradhan AA, Yu XH, Laird JM (2010). Modality of hyperalgesia tested, not type of nerve damage, predicts pharmacological sensitivity in rat models of neuropathic pain. Eur J Pain 14:503–509.
Przybysz KR, Varlinskaya EI, Diaz MR (2020). Age and sex regulate kappa opioid receptor-mediated anxiety-like behavior in rats. Behav Brain Res 379:112379.
Qi X, Guzhva L, Yang Z, Febo M, Shan Z, Wang KKW, Bruijnzeel AW (2016). Overexpression of CRF in the BNST diminishes dysphoria but not anxiety-like behavior in nicotine withdrawing rats. Eur Neuropsychopharmacol 26:1378–1389.
Renczés E, Borbélyová V, Keresztesová L, Ostatníková D, Celec P, Hodosy J (2020). The age-dependent effect of pre-pubertal castration on anxiety-like behaviour in male rats. Andrologia 52:e13649.
Rezayof A, Hosseini SS, Zarrindast MR (2009). Effects of morphine on rat behaviour in the elevated plus maze: the role of central amygdala dopamine receptors. Behav Brain Res 202:171–178.
Riley J, Eisenberg E, Müller-Schwefe G, Drewes AM, Arendt-Nielsen L (2008). Oxycodone: a review of its use in the management of pain. Curr Med Res Opin 24:175–192.
Saitoh A, Kimura Y, Suzuki T, Kawai K, Nagase H, Kamei J (2004). Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents. J Pharmacol Sci 95:374–380.
Scholl JL, Afzal A, Fox LC, Watt MJ, Forster GL (2019). Sex differences in anxiety-like behaviors in rats. Physiol Behav 211:112670.
Seth P, Rudd RA, Noonan RK, Haegerich TM (2018). Quantifying the epidemic of prescription opioid overdose deaths. Am J Public Health 108:500–502.
Srivastava AB, Mariani JJ, Levin FR (2020). New directions in the treatment of opioid withdrawal. Lancet 395:1938–1948.
Stock H, Foradori C, Ford K, Wilson MA (2000). A lack of tolerance to the anxiolytic effects of diazepam on the plus-maze: comparison of male and female rats. Psychopharmacology (Berl) 147:362–370.
Sudakov SK, Nazarova GA, Alekseeva EV, Kolpakov AA (2015). Peripheral administration of a μ-opioid receptor agonist DAMGO suppresses the anxiolytic and stimulatory effects of caffeine. Bull Exp Biol Med 158:295–297.
Sui-Hui L, Yu-Hui2Δ L, Xiao-Wei Y, Dong-Yan L, Yan C (2013) Oxycodone hydrochloride improves the anxiety and depression in patients with moderate and severe cancer pain. Chin J Pain Med 7.
Sullivan M, Edlund M, Zhang L, Unutzer J (2006). Depression and anxiety disorders predict increased use of prescribed opioids for non-cancer pain. J Pain 7:S50.
Tan S, Xue S, Behnood-Rod A, Chellian R, Wilson R, Knight P, et al. (2019). Sex differences in the reward deficit and somatic signs associated with precipitated nicotine withdrawal in rats. Neuropharmacology 160:107756.
Walf AA, Frye CA (2007). The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc 2:322–328.
Yang PP, Yeh GC, Yeh TK, Xi J, Loh HH, Law PY, Tao PL (2016). Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice. Pharmacol Res 111:867–876.
Zacny JP, Gutierrez S, Kirulus K, McCracken SG (2011). Psychopharmacological effects of oxycodone in volunteers with and without generalized anxiety disorder. Exp Clin Psychopharmacol 19:85–94.